[FROM EVIDENCE-BASED MEDICINE TO PERSONALIZED MEDICINE IN CROHN'S DISEASE].
The therapeutic armamentarium in Crohn's disease includes mesalazine, steroids (including topical drugs), anti-metabolites (purines, methotrexate), anti-TNFα antibodies and, more recently, selective inhibitors of lymphocytes homing (vedolizumab). The efficacy of these drugs has been shown in pivotal phase 3 placebo-controlled trials and meta-analyses. However, the use of these drugs in routine practice still remains ill-defined. Those are rather the cohort studies, natural history data and therapeutic strategy trials that help the clinician to determine, for each individual patient, the treatment leading to an optimal benefit/risk profile, aiming at moving from evidence-based medicine towards personalized medicine.
E
E
Louis
C
C
Reenaers
C
C
Van Kemseke
P
P
Latour
J
J
Belaiche
P
P
Meunier
C
C
Coïmbra
D002755:Choice Behavior; D003424:Crohn Disease / Q000188:drug therapy*; D019317:Evidence-Based Medicine / Q000379:methods / Q000639:trends*; D006801:Humans; D057285:Precision Medicine / Q000379:methods*; D012008:Recurrence; D055502:Secondary Prevention / Q000379:methods